UCB SA (OTCMKTS:UCBJF) Receives Consensus Rating of “Buy” from Brokerages

Shares of UCB SA (OTCMKTS:UCBJF) have been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating.

A number of research analysts have recently issued reports on UCBJF shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research assumed coverage on shares of UCB in a research report on Monday, February 23rd. They set an “outperform” rating for the company. Stephens restated an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Finally, Barclays reaffirmed an “overweight” rating on shares of UCB in a research report on Tuesday, January 6th.

UCB Stock Up 8.5%

Shares of UCB stock opened at $325.56 on Tuesday. The company has a 50-day simple moving average of $310.66 and a two-hundred day simple moving average of $295.30. UCB has a one year low of $168.65 and a one year high of $345.39. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.